Abbott Launches Updated Oncodetect Test to Enhance Minimal Residual Disease Detection
Abbott has introduced an updated version of its Oncodetect molecular residual disease test, according to Dr. Rick Baehner, the company is chief medical officer for precision oncology. The diagnostic tool is designed to identify tiny traces of cancer remaining in the body after initial treatment, addressing a critical need in ongoing patient monitoring.
Understanding Minimal Residual Disease Testing
Minimal residual disease, or MRD, testing helps clinicians detect microscopic levels of cancer cells that may remain after surgery, chemotherapy, or radiation therapy. Spotting these lingering cells early can help healthcare providers monitor treatment efficacy and watch for potential recurrence.
Insights from Abbott Leadership
In a discussion with MedTech Dive, Dr. Rick Baehner outlined how the revised Oncodetect platform performs in clinical settings and discussed the broader market landscape it enters. The updated technology aims to provide physicians with more sensitive and accurate data when evaluating patient prognosis.
- Designed to detect trace levels of cancer cells post-treatment
- Aims to support personalized precision oncology strategies
- Addressed by Abbott leadership in recent industry discussions
As diagnostic companies continue to refine molecular assays, tests like Oncodetect represent an ongoing effort to improve post-treatment surveillance for cancer patients. Further clinical studies will be necessary to establish long-term patient outcomes associated with the updated platform.
